Agreement of self-reported estrogen use with prescription data: An analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE)

Menopause

Volumn 15, Issue 2, 2008, Pages 282-289

  Sandini, Lorenzo ^a,b   Pentti, Kati ^a   Tuppurainen, Marjo ^a,b   Kröger, Heikki ^a,b   Honkanen, Risto ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Hormone therapy; Population based; Postal inquiry; Self report

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; BONE FRAGILITY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; FINLAND; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SELF MEDICATION; TREATMENT DURATION;

AGED; DATA COLLECTION; ESTROGENS; FEMALE; FINLAND; HEALTH SURVEYS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OSTEOPOROSIS; POSTAL SERVICE; REPRODUCIBILITY OF RESULTS; SELF ADMINISTRATION;

EID: 40449124088     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181334b6c     Document Type: Article

References (42)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-1049.
3. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
4. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997;145:536-545.
5. Seshadri S, Zornberg GL, Derby LE, Myers MW, Jick H, Drachman DA. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol 2001;58:435-440.
6. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-1112.
7. Merlo J, Berglund G, Wirfalt E, et al. Self-administered questionnaire compared with a personal diary for assessment of current use of hormone therapy: an analysis of 16,060 women. Am J Epidemiol 2000;152:788-792.
8. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-1465.
9. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-1480.
10. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
11. Gordis L. Assuring the quality of questionnaire data in epidemiologic research. Am J Epidemiol 1979;109:21-24.
12. West SL, Strom BL, Poole C. Validity of Pharmacoepidemiologic Drug and Diagnosis Data In: Storm BL, ed. Pharmacoepidemiology. 3rd ed. Chichester, UK: John Wiley & Sons, 2000:661-705.
13. Goodman MT, Nomura AM, Wilkens LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990;131:815-825.
14. Horwitz RI, Feinstein AR, Stremlau JR. Alternative data sources and discrepant results in case-control studies of estrogens and endometrial cancer. Am J Epidemiol 1980;111:389-394.
15. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-122.
16. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW. Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases. Am J Epidemiol 1981;114:497-506.
17. Persson I, Bergkvist L, Adami HO. Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol 1987;16:222-228.
18. Honkanen RJ, Honkanen K, Kroger H, Alhava E, Tuppurainen M, Saarikoski S. Risk factors for perimenopausal distal forearm fracture. Osteoporos Int 2000;11:265-270.
19. Juntunen M, Niskanen L, Saarelainen J, Tuppurainen M, Saarikoski S, Honkanen R. Changes in body weight and onset of hypertension in perimenopausal women. J Hum Hypertens 2003;17:775-779.
20. Pentti K, Honkanen R, Tuppurainen MT, Sandini L, Kroger H, Saarikoski S. Hormone replacement therapy and mortality in 52-to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. Eur J Endocrinol 2006;154:101-107.
21. Randell KM, Honkanen RJ, Komulainen MH, Tuppurainen MT, Kroger H, Saarikoski S. Hormone replacement therapy and risk of falling in early postmenopausal women - a population-based study. Clin Endocrinol (Oxf) 2001;54:769-774.
22. Sirola J, Kroger H, Sandini L, et al. Interaction of nutritional calcium and HRT in prevention of postmenopausal bone loss: a prospective study. Calcif Tissue Int 2003;72:659-665.
23. Sirola J, Kroger H, Honkanen R, et al. Factors affecting bone loss around menopause in women without HRT: a prospective study. Maturitas 2003;45:159-167.
24. Sirola J, Kroger H, Honkanen R, et al. Smoking may impair the bone protective effects of nutritional calcium: a population-based approach. J Bone Miner Res 2003;18:1036-1042.
25. Sirola J, Kroger H, Honkanen R, et al. Risk factors associated with peri- and postmenopausal bone loss: does HRT prevent weight loss-related bone loss? Osteoporos Int 2003;14:27-33.
26. Sirola J, Rikkonen T, Tuppurainen M, Jurvelin JS, Kroger H. Association of grip strength change with menopausal bone loss and related fractures: a population-based follow-up study. Calcif Tissue Int 2006;78:218-226.
27. Tuppurainen M, Kroger H, Saarikoski S, Honkanen R, Alhava E. The effect of gynecological risk factors on lumbar and femoral bone mineral density in peri- and postmenopausal women. Maturitas 1995;21:137-145.
28. Tuppurainen M, Kroger H, Honkanen R, et al. Risks of perimenopausal fractures - a prospective population-based study. Acta Obstet Gynecol Scand 1995;74:624-628.
29. Topo P, Koster A, Holte A, et al. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. Maturitas 1995;22:89-95.
30. Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas 1996;23:47-53.
31. Topo P, Klaukka T, Hemminki E, Uutela A. Use of hormone replacement therapy in 1976-89 by 45-64 year old Finnish women. J Epidemiol Community Health 1991;45:277-280.
32. Topo P, Luoto R, Hemminki E, Uutela A. Declining socioeconomic differences in the use of menopausal and postmenopausal hormone therapy in Finland. Maturitas 1999;32:141-145.
33. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
34. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. 2: The Design and Analysis of Cohort Studies. Oxford, UK: University Press/IARC, 1987:41.
35. Hunter DJ, Manson JE, Colditz GA, et al. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56:373-378.
36. Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 2004;15:396-404.
37. Eiken P, Kolthoff N. Compliance with long-term oral hormonal replacement therapy. Maturitas 1995;22:97-103.
38. Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA. Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities. Am J Epidemiol 1993;137:1125-1135.
39. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553.
40. Rosenberg L, Shapiro S, Kaufman DW, Slone D, Miettinen OS, Stolley PD. Patterns and determinants of conjugated estrogen use. Am J Epidemiol 1979;109:676-686.
41. Shah S, Harris TJ, Cook DG. Differences in hormone replacement therapy use by social class, region and psychological symptoms. BJOG 2001;108:269-275.
42. Marks NF, Shinberg DS. Socioeconomic status differences in hormone therapy. Am J Epidemiol 1998;148:581-593.